Simon Tate has 21 years of experience in drug discovery and development, 16 years of which in ion channels and pain. Simon was instrumental to the acquisition of Convergence Pharmaceuticals’ clinical assets from GSK, where he was previously VP, Pain and Epilepsy Discovery Performance Unit. At GSK, Simon delivered successful Phase II studies in pain, clinical candidates and novel targets. An authority in sodium channels and pain (>30 publications) Simon was a pioneer of sodium channel cloning and functional expression and in 1997 he set up a visionary multi-disciplinary ion channel discovery section, one of the first in the pharmaceutical industry. Simon led a paradigm shift for ion channel screening in GSK, implementing new platform technology through collaborations and alliances. Several ion channel projects have now progressed into the clinic as a consequence of this initiative and investment in ion channel research. He led the stem cell therapeutic area review, leading to a $25m cross disease alliance with the Harvard Stem Cell Institute. Earlier at GSK, Simon established and led the Neurosciences Discovery Technology Group, spanning Psychiatry and Neurology target validation and biomarker discovery and also established the department of Gene Expression and Protein Biochemistry in Stevenage.